NDAC Panelists Look At Future Of Behavior Research For OTC Postmarket
This article was originally published in The Tan Sheet
Executive Summary
FDA's Andrea Leonard-Segal, MD, expressed interest in a test-market approach to Rx-to-OTC switches during a recent advisory panel meeting